CatalystMarker
← board

STA

Starton Therapeutics, Incdistress 4/10 · elevated risk
Oncology 1
Lead: Multiple Myeloma · est. market ~$25B (approx, global)
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
—

Pipeline stages · 1 programs

Lenalidomide, Lenalidomide 25 MG Oral Capsule
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved

Pipeline · 1 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2026-05-31
Phase 1/2Lenalidomide, Lenalidomide 25 MG Oral CapsuleMultiple Myeloma24recruiting

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: — · 0 offerings/1y · 0 PIPEs
  • 2026-07-13S-1/Ashelf_registration
  • 2026-06-09S-1/Ashelf_registration
  • 2026-04-07S-1/Ashelf_registration
  • 2026-03-13S-1/Ashelf_registration
  • 2026-01-30S-1/Ashelf_registration
  • 2025-12-11S-1shelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors — Multiple Myeloma

  • JNJJOHNSON & JOHNSON$617.4B · D0
  • ABBVAbbVie Inc.$451.1B · D2
  • GSKGSK plc$217.0B · D1
  • PFEPFIZER INC$142.2B · D3
  • BMYBRISTOL MYERS SQUIBB CO$124.5B · D0
  • REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
  • CCCCC4 Therapeutics, Inc.$408M · D5
  • CRBUCaribou Biosciences, Inc.$160M · D0
  • TPSTTempest Therapeutics, Inc.$14M · D10
  • AZNASTRAZENECA PLC— · D3

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.